Moderna
Moderna price
About Moderna
Moderna, Inc., et bioteknologiselskap, er dedikert til oppdagelse, utvikling og kommersialisering av terapier basert på budbringer-RNA (mRNA) og forebyggende medisiner. Deres omfattende forsknings- og utviklingsarbeid retter seg mot et bredt spekter av medisinske behov, inkludert infeksjonssykdommer, kreftimmunologi, sjeldne tilstander, hjerte- og karsykdommer og autoimmune sykdommer, med virksomhet i USA, Europa og andre globale markeder. Selskapets mangfoldige produktpipeline omfatter ulike vaksinekandidater: de for luftveissykdommer som COVID-19, influensa og respiratorisk syncytialvirus (RSV); latente virusinfeksjoner som cytomegalovirus (CMV), Epstein-Barr-virus (EBV), humant immunsviktvirus (HIV), herpes simplex-virus (HSV) og varicella-zoster-virus (VZV); og folkehelsetrusler som Zika og Nipah. I tillegg fremmer Moderna systemiske sekreterte og celleoverflatemålrettede terapier, en rekke kreftvaksiner (inkludert personlige KRAS og checkpoint-varianter), intratumorale immunoonkologiprodukter, lokaliserte regenerative behandlinger, systemiske intracellulære medisiner og inhalerte lungeløsninger. Moderna opprettholder strategiske allianser med flere fremtredende aktører, inkludert AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research and Development Authority (BARDA), Institute for Life Changing Medicines og The Bill & Melinda Gates Foundation. Det har også en samarbeids- og lisensavtale med Chiesi Farmaceutici S.P.A. Selskapet ble grunnlagt i 2010 som Moderna Therapeutics, Inc., og ble offisielt Moderna, Inc. i august 2018. Hovedkontoret ligger i Cambridge, Massachusetts.
- Aksjesymbol
- MRNA
- Selskap
- Moderna, Inc.
- Industri
- Helsevesenet
- Kategori
- US
- Aksjesplitt / omvendt splitt
- --
- Lanseringsdato
- 7. des. 2018
- Notert børs
- NASDAQ
Finansielle forhold
Sammendrag: MRNA reported Revenue of 145.00M (+2,11 %), beating expectations; EPS of −1,97 (+7,51 %), beating expectations.
Moderna conversion tables
 |  |
|---|---|
| 0.5 MRNA | 96,67 USD |
| 1 MRNA | 193,34 USD |
| 5 MRNA | 966,72 USD |
| 10 MRNA | 1 933,45 USD |
| |
|---|---|
| 0.5 USD | 0,0025861 MRNA |
| 1 USD | 0,0051721 MRNA |
| 5 USD | 0,025861 MRNA |
| 10 USD | 0,051721 MRNA |
More to explore
FAQ
MRNA is trading at $193,35, +3,14 % over the last 24 hours. Track live moves on the price chart at the top of this page.
The MRNA stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. MRNA is currently trading at $193,35, +3,14 % over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on MRNA price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Helsevesenet sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. MRNA's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from MRNA; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against MRNA's historical range and other companies in the Helsevesenet sector.
Moderna, Inc.'s market cap is currently 75,95 mrd. USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.